Reference Study ID Number: GO43860 https://forpatients.roche.com/

CONTACT

Lead Sponsor

Genentech, Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Life expectancy at least 12 weeks
•Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
•Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1
•Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
•Tumor Specimen availability

•Pregnant or breastfeeding or intention of becoming pregnant during the study or within 4 months after the final dose of RO7501275, or 4 months after the final dose of pembrolizumab, or 5 months after the final dose of atezolizumab
•Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment
•Active hepatitis B or C or tuberculosis
•Positive test for human immunodeficiency virus (HIV) infection
•Acute or chronic active Epstein-Barr virus (EBV) infection at screening
•Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7502175 infusion
•Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
•Active or history of autoimmune disease
•Prior allogeneic stem cell or organ transplantation

Related studies

NCT06043817 · Non-Small Cell Lung Cancer, NSCLC, and more

NCT07363252 · EGFR-mutated NSCLC

NCT06758401 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, and more

NCT06476808 · High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), and more

NCT07528066 · Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, and more

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors